R-MVST Cells for Treatment of Viral Infections in Children and Young Adults

PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 20, 2025

Primary Completion Date

April 30, 2029

Study Completion Date

December 31, 2030

Conditions
Epstein-Barr VirusCytomegalovirus InfectionsAdenovirusBK Virus InfectionImmune Deficiency
Interventions
DRUG

Rapidly generated virus specific T (R-MVST) cells

"Group A dose escalation schedule:~* Cohort (-1A): 0.25x10\^6 R-MVST TNC/kg~* Cohort (1A): 0.5x10\^6 R-MVST TNC/kg~* Cohort (2A): 1x10\^6 R-MVST TNC/kg~Groups B \& C dose escalation schedule:~* Cohort (-1B) + (-1C): 1x10\^6 R-MVST TNC/kg~* Cohort (1B) + (1C): 2x10\^6 R-MVST TNC/kg~* Cohort (2B) + (2C): 4x10\^6 R-MVST TNC/kg"

Trial Locations (1)

10032

RECRUITING

Columbia University Medical Center / New-York Presbyterian, New York

All Listed Sponsors
lead

Columbia University

OTHER